Date:2/4/2008

nts in the combined REMICADE groups (3mg/kg and 5 mg/kg) experienced similar improvement in PASI scores of the upper and lower extremities. For the upper extremities the proportions of patients achieving at least 75 percent improvement or at least 90 percent improvement versus placebo were as follows: SPIRIT, 77 percent versus 6 percent achieved at least 75 percent improvement and 49 percent versus 2 percent achieved at least 90 percent improvement; EXPRESS, 82 percent versus 4 percent achieved at least 75 percent improvement and 56 percent versus 1 percent achieved at least 90 percent improvement; EXPRESS II, 72 percent versus 2 percent achieved at least 75 percent improvement and 46 percent versus 0.5 percent achieved at least 90 percent improvement. Results for the lower extremities were: SPIRIT, 72 percent versus 8 percent achieved at least 75 percent improvement and 49 percent versus 2 percent achieved at least 90 percent improvement; EXPRESS, 75 percent versus 3 percent achieved at least 75 percent improvement and 50 percent versus 1 percent achieved at least 90 percent improvement; EXPRESS II, 65 percent versus 4 percent achieved at least 75 percent improvement and 35 percent versus 0.5 percent achieved at least 90 percent improvement.

Further results from the integrated analysis were published in the summer 2007 issue of the Psoriasis Forum, a journal of the National Psoriasis Foundation, and showed the consistency of REMICADE response across subgroups defined by a variety of baseline demographic and disease characteristics in patients with psoriasis. REMICADE was similarly effective regardless of previous use of phototherapy or major conventional systemic therapies.(i)

About EXPRESS

EXPRESS was a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of REMICADE induction and maintenance therapy in 378 adult patients with chronic, stable plaque psoriasis involving at least 10 per
'/>"/>

SOURCE Centocor, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients